New research affiliated with the University of Colorado at Boulder and published in Psychology of Addictive Behaviors reveals that consumption of CBD-dominant cannabis may be associated with reduced alcohol intake.
In order to test this, the researchers looked at cannabis use across 120 subjects and compared use of cannabis that was primarily CBD-heavy, THC-heavy, or a mix of both. This revealed that those who used CBD-dominant cannabis “drank fewer drinks per drinking day, had fewer alcohol use days, and fewer alcohol and cannabis co-use days compared with the other groups.” Those who used THC/CBD cannabis or THC-only did not experience any reduced alcohol intake or change in their drinking patterns.
“Conflicting evidence exists regarding the effects of cannabis on alcohol consumption, with some studies suggesting that cannabis is a substitute for alcohol, whereas others suggest that cannabis complements alcohol, thereby increasing drinking. Cannabidiol (CBD) has shown preclinical promise in decreasing alcohol consumption,” the researchers explained “This study explores the effects of cannabis containing different potencies of CBD and delta-9-tetrahydrocannabinol (THC) on alcohol consumption.
The authors also claimed that the results of reduced alcohol intake were “consistent with preclinical work suggesting that CBD may be associated with decreased alcohol consumption.” Other, past studies that looked at CBD vs. opiates, heroin, tobacco, and other controlled substances revealed similar results.
They concluded: “The present study lends preliminary support to the notion that plant-based CBD may be associated with decreased alcohol consumption among regular cannabis users and suggests that it may be feasible for regular cannabis users to switch to a higher CBD, lower THC content cannabis strain for the purposes of reducing their alcohol intake.”
The study further requested that cannabinoid content, or the makeup of cannabis, be studied when comparing alcohol and cannabis use because it clearly makes a difference whether or not cannabis is CBD- or THC-heavy.
Reduced Alcohol Intake And Cannabis Use
This isn’t the first study of its kind to look at the association between cannabis use and reduced alcohol intake. The study’s co-authors released a similar research project in January which was published in the Addiction journal showed an inverse relationship between cannabis and alcohol use. Those who were chronic alcohol users had reduced consumption on days when they used cannabis.
That study, conducted by the University of Colorado at Boulder and Colorado State University looked at 96 different subjects who used cannabis and were also enrolled in an alcohol abuse treatment program. Their use fell on days when they used cannabis, and this trend was consistent among those with heavy cannabis use and light cannabis use.
They research team claimed: “Across the sample, individuals drank approximately 29 percent fewer drinks and were 2.06 times less likely to have a binge-drinking episode on days that cannabis was used compared with days cannabis was not used. These patterns were observed in males, females and the infrequent and frequent cannabis use groups.”
“Heavy drinkers engaged in treatment to reduce their alcohol consumption who also use cannabis appear to increase their cannabis use on days when they reduce their alcohol consumption,” they concluded.
About this study, NORML Deputy Director Paul Armentano added, “Several previous studies have examined whether cannabis is more likely to act as either a substitute or as a compliment for alcohol and, thus far, they have yielded mixed results. This study’s findings are an important addition to this growing body of literature and offer strong evidence that cannabis can act as an intervention for certain persons seeking to reduce their alcohol consumption.”
While more research still needs to be done on this topic, it is clear from the data so far that cannabis, especially CBD-dominant cannabis, can be helpful in patterns of reduced drinking.
Warning: sprintf(): Too few arguments in /home/prosofte/domains/vaporizers.pl/public_html/wp-content/themes/blogito/inc/template-tags.php on line 319
Canadian pot firms eye well-trodden path to U.S. through CBD sales
The pathway to the U.S. cannabis market is being closely watched by Canadian companies eager to enter the frenzied space. But an already well-trodden path exists for those companies seeking an early advantage over their Canadian peers – CBD. As the U.S. cannabis market remains closed due to the drug still illegal federally – though more than half of the country’s states have passed measures allowing its sale for either medical or recreational purposes – Canadian companies have begun to move in earnest to establish a U.S. presence solely in the CBD space. Products containing only CBD, the chemical compound derived from the cannabis plant that doesn’t impair users, have been allowed for sale across the U.S. in the wake of the passage of the 2018 Farm Bill. The U.S. Food and Drug Administration (FDA) is also investigating how to regulate CBD for ingestible use, although it’s unclear when it plans to make a formal decision.
Cannabis extractor Valens Co. was the latest to pursue that strategy after it agreed to buy Florida-based Green Roads for US$40 million in cash and stock, plus an additional US$20 million if certain sales milestones are met. Other companies that employed a U.S. CBD strategy include Aurora Cannabis Inc., Cronos Group Inc., Canopy Growth Corp., Tilray Inc., and retailer High Tide Inc. „Our intention is to go down there, optimise a few of their opportunities and then basically build around that management team to continue to basically forge forward until THC becomes legal in the U.S.,” said Tyler Robson, Chief Executive Officer at Valens in a phone interview. „We believe the opportunity in Canada is still big, but the U.S. is bigger.” But the U.S. CBD market isn’t a guaranteed home run for some market entrants. While sales of CBD products in the U.S. are expected to rise to US$16.8 billion by 2025 from US$4.7 billion last year, the market has roughly 1,500 brands offering a relatively commoditized product, making it somewhat difficult for some companies to stand out, said Bethany Gomez, managing director of Brightfield Group, a cannabis consultancy. „The Canadian market is more constrained than what many companies initially thought with some well-capitalized producers duking it out for a relatively small pool. The CBD market gives them the ability to add more revenue to their top line,” Gomez said in a phone interview.
Philip Morris looking at cannabis for potential investment: CEO
Marlboro-maker Philip Morris International is said to be taking a closer look at the cannabis industry, according to Bloomberg News. The company’s CEO told Bloomberg News the firm was investigating cannabis’ toxicity and efficacy to determine whether it intends to invest in the sector, although it has yet to do so. „Our priority is what we’re doing with our smoke-free products, and that’s where I would stay on cannabis,” said Andre Calantzopoulos. Other tobacco producers such as Imperial Brands, Altria and British American Tobacco have already linked up with Canadian cannabis producers in an attempt to diverisify their businesses as the U.S. appears poised to legalize marijuana sometime soon.
Cannabis added $17.1B in economic activity in February: StatsCan
Canada’s cannabis industry contributed $17.1 billion in economic activity in February, an increase from the $11.9 billion in output recorded a year earlier, according to Statistics Canada. The country’s legal cannabis market representated about $11.7 billion in gross domestic product, nearly double the amount reported back in February 2020, StatsCan found. The illicit market continued to trend downward from recent month to $3.69 billion from $4.18 billion a year ago. Canada’s cannabis industry contributes more to the country’s GDP than its pharmaceutical industry, plastics manufacturing, motor vehicles and parts manufacturing, health and personal care retailers, rail transportation and insurance brokerages, the StatsCan data showed.
TGOD mulls Quebec facility sale, possible listing on CSE for U.S. entry
The Green Organic Dutchman released a wide-ranging corporate update on Thursday. The Toronto-based company said it has closed the first round of bidding on its Valleyfield facility in Quebec – a year after it suspended production at the building – and expects to close its sale by the end of June. TGOD said it already made $2.6 million in various asset sales to date. The company is also eyeing a U.S. market entry, with a potential listing on the Canadian Securities Exchange as well as adding a board member with U.S. experience. Lastly, TGOD said it has retained Canaccord Genuity to advise on a possible sale or spinoff of its HemPoland subsidiary.
Ontario Cannabis Store launches new craft badge for smaller producers
Ontario’s cannabis wholesaler and online retailer launched a new craft designation Thursdayaimed at boosting sales for smaller cannabis producers. The craft badge – which has been in the works at the Ontario Cannabis Store for quite some time – applies to products which have been made by a company that hand-trimmed, hang-dried, hand-packaged, and grew its cannabis in a facility that produces less than 10,000 kilograms of dried flower per year. The classification includes 20 producers and only applies to dried flower and pre-rolls, although it could add additional categories in the future, MJBizDaily reports.
Quarterly Results Wrap: GTEC, Fire & Flower, Gage
Here’s a summary of some of the cannabis industry companies that reported quarterly results this week:
GTEC Holdings: First quarter 2021 revenue down 15 per cent to $1.97 million, $199,000 in adjusted EBITDA loss, compared to a $5,000 gain a year earlier. (Release)
Fire & Flower: Fourth quarter revenue up 157 per cent to $43.2 million, $1.5 million in adjusted EBITDA, compared to a $5.2 million loss a year earlier. (Release)
Khiron Life Sciences: Fourth quarter revenue little was changed to $2.5 million, $4.4 million in adjusted EBITDA loss, compared to a $6.3 million loss a year earlier. (Release)
Gage Growth: Fiscal 2020 revenue was US$39.9 million, compared to US$1.9 million in 2019. It reported a US$29.8 million net loss, compared to a US$75 million loss a year earlier. Gage forecast it would generate about US$18 million in Q1 2021 revenue, with sales nearly doubling in the forthcoming quarter. (Release)
Auxly Cannabis: Fourth quarter revenue was $18.3 million, compared to $3.2 million a year earlier. It reported a $6.1 million adjusted EBITDA loss, compared to a $10.5 million loss a year earlier. (Release)
Analyst Call of the Week – Canadian cannabis retail sales
Canada reported about $263 million in cannabis sales in February, a decline of 6.3 per cent from the prior month, but up about four per cent on a per-day basis from January, according to Statistics Canada. Most provinces, except for Ontario, reported sales declines in the month, StatsCan found. Cantor Fitzgerald Analyst Pablo Zuanic said the country’s retail sales trends are better than what was first feared, even accounting for the seasonality of retail activity following the holiday-fuelled year-end period. Zuanic pointed to early retail figures from data provider Hifyre that suggest March will be a bounce-back month with projected sales seen to climb 17 per cent, while an early analysis of April figures suggests another modest increase. „Clearly, this shows improving trends at retail in March and April,” Zuanic said. „We would anticipate StatsCan reporting April sales up 2 per cent and 5 per cent in day-adjusted terms.”
CANNABIS SPOT PRICE: $5.77 per gram — This week’s price is up 0.8 per cent from the prior week, according to the Cannabis Benchmark’s Canada Cannabis Spot Index. This equates to US$2,114 per pound at current exchange rates.
WEEKLY BUZZ
„Cannabis is not a gateway to drugs. It’s a pathway to healing.”
Germany, along with the rest of the Europe, seems to be opening up to the idea of researching, and accepting, the many benefits of the cannabis plant.
This is significant in view of the fact that only several months ago, hemp vendors were arrested and convicted in Braunschweig for selling hemp tea leaves. The case however was later overturned by Germany’s Federal Court of Justice.
And now the German government is funding a Berlin-based food startup, Becanex GmbH, to the tune of 505,000 euros ($601,720) to create cannabinoid-containing emulsions for industrial food production, reports High Times.
What makes the investment so important, reports High Times, is that the funding entity, the Central Innovation Programme for Small and Medium-Sized Enterprises, is under the German Federal Ministry for Economic Affairs and Energy, which is “about as central to German economic investment in the future as you can get.”
The move will likely not go unnoticed throughout Europe. It was only in November that the European Court of Justice ruled that CBD is not a narcotic. The consequences of that ruling are being felt today as commercialization begins to take off.
In addition to Becanex’s food research, HempToday reported that Düsseldorf-based Hempro International GmbH has submitted an application to Germany’s Consumer Protection and Food Safety office that would allow it to import hemp leaves from Austria to Germany to make, yes, hemp tea!
Currently, Germany allows cultivation of hemp with less than 0.2% THC, and also the purchase of CBD products with the same amount of THC, although CBD edibles are illegal, under the Novel Food Regulation in Europe.
Green Lobster CBD Gummies are made from full-spectrum pure hemp cannabidiol extract. Each neon cube contains a powerful dose of 25mg CBD. Most people could be wondering why full-spectrum CBD is becoming popular with each passing day.
Do the Lobster CBD Gummies work? Do they have negative side effects that users need to know before using them for the first time? Read on to discover more about this product in this review.
These gummies contain CBD as the primary ingredient, which allows them to deliver all these benefits. Made of 100% pure hemp, they do not have any side effects that might endanger the health of the users.
What is CBD?
Cannabidiol (CBD) is a natural compound found in the hemp plant. It’s a popular natural remedy for many ailments. Three years since the USA passed the popular Farm Bill, researchers have discovered much more about the CBD compound.
Initially, the CBD compound was linked to the psychoactive properties of THC, another compound in the cannabis plant that is responsible for making people high. However, researchers have so far discovered many ways to activate the endocannabinoid system without delivering any psychotropic effect.
Consequently, many companies have developed various remedies to show what CBD can do. These remedies include tinctures or oils and CBD edibles. The Green Lobster Neon Cubes are CBD-infused gummies that fall in the category of edibles. These gummies make it easy for users to consume CBD and benefit from its healing properties. They work well for those who may not like the taste or topical application.
As mentioned in the Globe Newswire, Users of Green Lobster CBD Neon Cubes can enjoy a pain-free life, courtesy of the medicinal properties of the CBD. Pain relief is one of the primary benefits of CBD, especially the way it lowers inflammation. Additionally, CBD plays other roles and has an effect on the nervous system.
How Do CBD Edibles Work?
CBD edibles are available in many forms. They include tinctures, oils, gummies, cake pops, and chocolate bars. Compared to the inhaled CBD products, edibles offer longer-lasting alternatives.
CBD edibles have become ultra popular, with nearly every food and beverage having a CBD-infused version. These edibles provide a user-friendly way of consuming CBD and benefiting from its medicinal properties. CBD delivers a wide range of health benefits, but is mostly used to alleviate pain and inflammation.
Finding the right CBD product is one of the challenges that users face. With several companies out there, users might easily land on the products made without following ethical guidelines given by regulators. It is also difficult to know whether the chosen formula is pure and potent as claimed by the manufacturer.
Green Lobster, which is the manufacturer of the CBD Neon Cubes, allows customers to reach out to them for the lab reports and studies done on any of their CBD products. This gives assures the customers that their products are safe and the right solution.
Consequently, the Green Lobster CBD Neon Cubes have no risk to users. They don’t cause any addiction, because they are natural. According to the creators, these gummies can also help users break a smoking habit, improve their sleep, and get relief from pain and inflammation.
CBD is directly linked to the endocannabinoid system (ECS). The ECS is naturally found in the human body and is responsible for processing both the CBD and THC compounds. After ingestion or topical application of any form of CBD, it’s absorbed into the bloodstream, where it can activate the central nervous system.
CBD gummies are easy to break down and process because they are ingestible and can reach the bloodstream faster. Once consumed, the nutrients in the CBD gummies work to achieve the healing required. They can regulate the brain and body, which is the main reason most people feel more balanced and pain-free after using them.
The Science Behind CBD
The endocannabinoid system (ECS) is responsible for regulating nearly all body functions. It controls relaxation, inflammation, and even cognitive function. Concisely, the ECS makes sure the entire body works optimally. The Green Lobster CBD Gummies work to optimize the ECS by dealing with issues such as anxiety, chronic pain, insomnia, or inflammation.
The functioning of the ECS revolves around the following areas:
Body: It stimulates an anti-inflammatory response, which enables the body to reduce all forms of chronic aches and pains. Used regularly, these gummies help support joint health, mobility, and flexibility.
Brain: The ECS helps optimize moo patterns to lower anxiety and stress levels. Additionally, it improves sleep cycles. In some cases, it might relieve depression and bipolar disorders.
Age: Most chronic diseases such as cancer, diabetes, heart disease, and many others are caused by inflammation. With optimized ECS, users can manage most of these conditions.
According to recent articles from Harvard Medical School, CBD is the same compound that the Food and Drug Administration has approved to treat certain types of epilepsy, based on its natural healing properties.
Many scientists have studied the compound extensively for its ability to relieve anxiety and activate the CB1 and CB2 receptors of the ECS.
Together with the previously mentioned conditions that the CBD Neon Cubes could alleviate, CBD is linked to lowering high blood pressure, prevention of diabetes, and relieving pain and inflammation. The list is expected to grow as scientists continue to unravel more benefits of the Endocannabinoid System (ECS.)
Up to now, researchers agree that the ECS can help optimize the majority of the human body functions. It can support cognitive abilities and keep the entire body in complete balance. Besides, it supports a healthy inflammatory response and maintains joint health. Similarly, some people use it to treat depression and bipolar disorders, but this should not replace a medical prescription by a doctor.
Benefits of Using Green Lobster CBD Neon Cubes
Every person who takes a daily dose of the Green Lobster CBD Neon Gummies can get any of the benefits they offer. The gummies are tasty and easy to chew. They assimilate into the digestive system faster and easily deliver CBD properties. When the ECS attracts this compound, it provides the healing and support to relieve pain, anxiety, and improve sleep.
Additionally, it provides a general balance for the central nervous system. According to the manufacturer, users begin to feel the effects of the CBD as soon as they consume the supplement and continue using it. While it doesn’t deliver any psychoactive effects, it doesn’t cause any form of addiction.
The Green Lobster CBD Gummies were made to help users enjoy the taste while keeping their bodies regulated. From the moment a user takes the first bite of a Green Lobster CBD gummy, it delivers CBD that helps regulate the ECS.
Consequently, the user can have control over pain, anxiety, sleep, and overall body balance. This is the first step in using this supplement.
In the second step, it delivers natural and fast relief. The manufacturer advises users that their results with CBD improves in proportion to their continued use. Importantly, CBD is 100% non-habit forming. Users can take it daily without delivering any psychoactive effects. Additionally, it comes with a 100% satisfaction guarantee.
In the third and final step, the supplement transforms the life of the user. It delivers a proper dose to the body, so the user can feel good throughout the day. The user continues to enjoy the benefits of CBD superior delivery and absorption.
Green Lobster CBD Gummies Price
The Green Lobster CBD Neon Cubes are available for purchase on the official website at https://www.greenlobstercbd.com/deal/. New customers have to first register on this website before they can place their orders. After registration, they can view the available packages and choose their preferred units.
A single-bottle package attracts a $5.95 shipping fee. However, buyers of multi-bottle packages can enjoy free shipping. The current prices are:
All the prices on the website can change without notice. The price charged for a product remains in effect at the time the buyer places the order, as set out in the confirmation order e-mail. Any questions regarding orders can be channeled to the customer service team through an e-mail to customercare@greenlobstercbd.com.
Alternatively, customers can call the department at 866-761-6304. According to the creator, the product is currently in high demand, which might affect its supply. Interested users should take advantage of the availability while stocks last.
Importantly, each order comes with a 100% moneyback guarantee. The manufacturer believes in the efficacy of the product. Therefore, they take on 100% of the risk and protect each order with a 60-day moneyback guarantee.
During this period, buyers can use the product without risking a dime. If for any reason it fails to work for you as expected, you can take advantage of the refund policy and ask for a refund.
Pros and Cons
The Pros
Made of 100% natural ingredients
Full-spectrum and water-soluble
Comes with a 100% satisfaction guarantee
Reduces pains and chronic aches
Relieves anxiety and stress
Can help users quit smoking
Promotes healthy sleep
Delivers powerful relief without getting high
500mg of potent, tasty gummies
Discounted prices
Made in the USA under an FDA-certified facility
The Cons
Available for purchase on the official website only
Limited stock
Green Lobster CBD Neon Cubes Verdict
The Green Lobster CBD Neon Cubes deliver a safe way to receive the therapeutic benefits of the cannabidiol (CBD) compound. This product has no habit-forming ingredients. It gives users the relief they could not afford before CBD was launched in the market.
The gummies come with an appetizing taste that makes them stomach-friendly. However, the creator warns that these gummies are simply a supplement and should not replace medical attention.
The links contained in this product review may result in a small commission if you opt to purchase the product recommended at no additional cost to you. This goes towards supporting our research and editorial team and please know we only recommend high quality products.
Disclaimer:
Please understand that any advice or guidelines revealed here are not even remotely a substitute for sound medical advice from a licensed healthcare provider. Make sure to consult with a professional physician before making any purchasing decision if you use medications or have concerns following the review details shared above. Individual results may vary as the statements made regarding these products have not been evaluated by the Food and Drug Administration. The efficacy of these products has not been confirmed by FDA-approved research. These products are not intended to diagnose, treat, cure or prevent any disease.
Cannabis stocks traded mostly in the green this week, as we got into earnings season.
“While there were a lot of companies reporting earnings, like Turning Point Brands who gave guidance of $422 million for 2021, I thought the biggest piece of data came from Pennsylvania,” Debra Borchardt, editor-in-chief of Green Market Report, told Benzinga. “The state reported that in one year it had sold over $900 million in medical marijuana. This demonstrates the demand for cannabis in this state and bodes well for any future adult-use legalization. This is also a big number when one considers that the program has only just gotten underway.”
And, while Pennsylvania sales surpassed $900 million in one year, Maryland sales finally hit $1 billion, more than three years after the medical cannabis program launched in December of 2017.
Meanwhile, the Swiss-American multinational Philip Morris International Inc. (NYSE: PM), maker of Marlboro cigarettes, said it’s considering getting into the cannabis industry. The company is currently analyzing key components of the industry, such as the “toxicity of cannabis, efficacy and differences between pharmaceutical and consumer options.”
CEO Andre Calantzopoulos reportedly said, “We are doing all this work and will determine one day what avenues to pursue… But our priority is what we’re doing with our smoke-free products, and that’s where I would stay on cannabis.”
Benzinga Cannabis’ content is now available in Spanish on El Planteo.
This is not the first foray of big tobacco into the cannabis industry. In 2018, Altria Group, Inc. (NYSE: MO) invested CA$2.4 billion ($1.8 billion) in Cronos Group, Inc. (NASDAQ: CRON), and only last month, British American Tobacco PLC (NYSE: BTI) confirmed a CA$221-million investment in OrganiGram Holdings, Inc. (NASDAQ: OGI)
ETFs posted mostly positive performances. Over the five trading days of this week:
The ETFMG Alternative Harvest ETF (NYSE: MJ): gained 1%.
The AdvisorShares Pure Cannabis ETF (NYSE: YOLO): advanced 2.8%.
The AdvisorShares Pure US Cannabis ETF (NYSE: MSOS): rose 6.7%.
The Amplify Seymour Cannabis ETF (NYSE: CNBS): was down 0.37%.
The SPDR S&P 500 ETF Trust (NYSE: SPY) closed the week almost flat.
On the policy front, U.S. lawmakers introduced a bipartisan, bicameral bill to study the various impacts of state-legalized cannabis programs. The bill would assess both medical and recreational cannabis programs and their economic, public health, criminal justice and workplace effects.
The study would also look at revenue streams generated by legal marijuana markets, how the revenue is used and how it impacts state budgets.
Aside from financial metrics, the study would look at consumption among population groups, medicinal usage and the impact of cannabis on the opioid crisis.
Policy, Science And Data
According to a recent report from the Brightfield Group, the U.S. cannabis market is set to reach $30.6 billion by 2025.
In Florida, two businesses looking to open medical cannabis dispensaries in downtown Miami have filed lawsuits against the city, which has refused to authorize dispensary openings, despite the fact that the state legalized medical cannabis in 2016 by way of a constitutional amendment that was passed with a 71% approval rate.
Texas continues to ease restrictions for its medical cannabis program. This week, several cannabis-related measures were approved in the House, including a proposal to research the potential of psychedelics such as psilocybin and MDMA and to expand the state’s medical cannabis program by adding more qualifying conditions to the list.
Under this bill, the Department of State Health Services would add cancer, chronic pain and post-traumatic stress disorder (PTSD) to its list of qualifying conditions. It could also raise the THC cap for medical cannabis products from 0.5% to 5%.
Financings And M&A
Green Thumb Industries Inc. (CSE: GTII) (OTCQX: GTBIF) raised $217 million to retire its existing $105-million senior secured debt due May 2023, finalizing a senior non-brokered private placement financing via the issuance of senior secured notes.
Sundial Growers Inc. (NASDAQ: SNDL) upped its financial commitment to SunStream Bancorp Inc. to $188 million – from the previously announced $100 million.
Back in March, the company first announced it has agreed to establish a 50/50 joint venture with the SAF Opportunities LP (a member of the SAF group) via a new corporation, SunStream Bancorp. The joint venture was created with a goal to produce investment opportunities in the cannabis sphere, by offering exposure to attractive debt, equity, and hybrid investments.
MedMen Enterprises Inc. (CSE: MMEN) (OTCQX: MMNFF) canceled warrants to acquire 97,785,140 Class B Subordinate Voting Shares of the company. The move comes after two consecutive quarters of positive retail cash flow.
Ascend Wellness Holdings, Inc. is poised to go public through an initial public offering of some 10 million shares of its Class A common stock at $8 per share, for total gross proceeds of $80 million.
The company expects to close the offering and then debut on the Canadian Securities Exchange on Tuesday, May 4 under the ticker symbol „AAWH.” An OTCQX Best Market listing is also anticipated.
Also this week, Ascend opened a new store in downtown Boston.
Acreage Holdings, Inc. (OTCQX: ACRGF) sold its Florida operations to Red White & Bloom Brands, Inc. (CSE: RWB) (OTCQX: RWBYF) for $60 million in cash, stock and vendor take-back promissory notes.
Columbia Care, Inc. (NEO: CCHW) (CSE: CCHW) (OTCQX: CCHWF) (FSE: 3LP) acquired a 34-acre cultivation facility in Long Island, New York in a $42.5-million stock-and-cash deal.
The Valens Company Inc. (TSX: VLNS) (OTCQX: VLNCF) is poised to take over Green Roads in a cash-and-stock transaction valued at $40 million.
Headset raised $1.825 million in a round led by Silverleaf Venture Partners. WGD Capital, L.P. and Poseidon also participated in the financing.
IM Cannabis Corp. (CSE: IMCC) (NASDAQ: IMCC)’s Israeli subsidiary, IMC Holdings Ltd., will acquire a trading house and in-house pharmacy activities from the Panaxia Labs Israel, Ltd. group of companies for $7.2 million.
Acquired Sales Corp. (OTCQX: AQSP) subsidiary Lifted Made and Savage Enterprises partnered to create an equally-owned new entity called LftdXSvg LLC to make and sell products containing hemp-derived THCV (tetrahydrocannabivarin).
Halo Collective Inc. (NEO: HALO) (OTCQB: HCANF) (FSE: A9KN) and Red Light Holland Corp. (CSE: TRIP) (FSE:4YX) (OTC: TRUFF) are forming a 50/50 joint venture.
Red Light Oregon, Inc. is poised to keep track of regulatory updates related to Oregon’s Measure 109, as well as form a management team and develop a commercialization strategy. It will be funded with $50,000 from each party.
Medical cannabis tech accelerator TechforCann Europe raised 2.5 million euros ($3 million) from Malta Enterprise, the island’s governmental innovation agency.
Earnings Reports
Harborside Inc (CSE: HBOR) (OTCQX: HBORF) reported that gross revenue grew by 29.4% year-over-year to roughly $63.4 million in fiscal 2020. Adjusted EBITDA came in positive, at $7.4 million for the same period, compared to an $8.9 million loss in 2019.
Fire & Flower Holdings Corp. (TSX: FAF) (OTCQX: FFLWF) reported it has generated CA$128.1 million (CA$103.2 million) in revenue at a gross profit of 35.5% in fiscal 2020. This represents 150% year-over-year growth.
Adjusted EBITDA came in positive, at CA$20,000 for the same period, compared to a CA$16.3 million loss in the fiscal year ended February 1, 2020.
Namaste Technologies Inc. (TSXV: N) (OTCQB: NXTTF) said that its gross revenue grew by 13% year-over-year to CA$6.15 million ($4.96 million) in the first quarter of 2021.
Net revenue for the first three months of the fiscal year amounted to CA$5.5 million, compared to CA$5.3 million in the same quarter of 2020, and CA$7.2 million in the prior quarter.
Growth Corp. (CSE: GAGE) generated $39.9 million in revenue at a gross margin of 30.8% in fiscal 2020, representing a 1,972% year-over-year increase.
The Ferndale, Michigan-based company, led by veteran cannabis industry executive Bruce Linton, also disclosed that its fourth-quarter revenue spiked 615% over the same period to $10.5 million.
Turning Point Brands, Inc. (NYSE: TPB), maker of Zig-Zag papers, said fourth quarter net sales grew by 31.2% to $105.3 million. Net income rose from $25.0 million to $12.7 million.
Guidance was also strong. The company said it expects net sales of $412 to $432 million for 2021.
The U.S. Department of Agriculture (USDA) entered into a new agreement with a chemical manufacturing company, Midwest Bioprocessing Center (MBC) to help expand the hemp seed oil-based cosmetic market.
TIME revealed its first-ever “TIME100 Most Influential Companies” list that highlights businesses making an extraordinary impact around the world. Included in the list was none other than Tilray Inc (NASDAQ: TLRY).
“Irwin Simon was best known for creating a health-food giant before signing on to head Aphria, a cannabis company based in Canada, where recreational marijuana is legal. Separately, Brendan Kennedy went to Nanaimo, British Columbia, to launch Tilray after co-founding a private-equity firm to buy cannabis startups. Now they’re merging the two to form the world’s largest cannabis company by annual revenue—more than $685 million,” said the magazine.
CBDistillery and Releaf app announced a strategic partnership for 2021. Together, the companies will analyze the efficacy of CBDistillery’s product catalog in addressing symptoms of stress, sleep, physical pain/discomfort, and anxiety. The first two studies focused on stress and sleep are accepting 1,000 volunteers for enrollment. Participants will receive products for free.
Tony Schwartz, director of strategic partnerships at CBDistillery, told Benzinga, “The alignment between Releaf app and CBDistillery is ideal in that we both are vested in providing consumers with trustworthy, objective, and reliable information on their journeys with CBD, CBG, and CBN.”
CanaQuest Medical Corp’s (OTC: CANQF) Mentanine demonstrated at least 10-times (10X) the efficacy compared to “Pharma Grade CBD” in preclinical trials undertaken by CanaQuest’s research partner in Ontario, Canada, Western University. Neuroscientist Dr. Steven Laviolette and his 13-member university research team managed the preclinical trials, which proved to be statistically significant.
“Our CBD-based Mentanine discovery works synergistically and has multiple times the efficacy compared to pure CBD products on the market. Evidence found that this formulation targeted a specific nuclear cellular receptor involved in anti-inflammatory mechanisms indicating that this formula may also treat inflammatory disorders,“ Western University neuroscientist Dr. Steven Laviolette told Benzinga.
Abaca announced a partnership with Staley Technologies and CIMA with the goal of digitizing cash management. The partnership delivers an integrated solution to cannabis operators, financial controllers, and CFOs with secure cash custody processes and real-time visibility on company cash across the organization.
“Abaca’s proud to offer a tech-forward solution to one of the last remaining analog aspects of the industry. Whether you are a multistate operator or a single dispensary, our partnership with Staley and CIMA brings our clients a seamless solution,” Abaca chief strategy officer Brian Bauer told Benzinga. „Authorized employees across the organization can log into Abaca Online Banking and see a real-time cash position and transaction log, in addition to being able to manage financial operations and send money.”
GCorp, a management and consulting services company founded by New York’s philanthropic Gilder Family, and Grow Industries Inc. (formerly ClimaGrow) entered into a definitive agreement, pursuant to which the Grow Industries brand will join GCorp’s portfolio of services.
Grow Industries founder Jesse Elkins told Benzinga, “Our industry is rapidly expanding, which means that operators need to overcome unique barriers, such as limited resources, finite bandwidth capacity and a lack of topic experts across the value chain. Our services at Grow Industries give MSOs, licensed producers and cannabis brand specialists the financial and technical solutions needed to thrive in both the short and the long term. The glaring marketplace gap between supply and demand for true, quality cultivation and manufacturing facilities is where we come in, allowing our clients to get that leg up they are looking for and take things to new heights.”
C3 Industries announced its High Profile Grand Rapids location has converted from medical to adult-use. CEO Ankur Rungta explained, “With the Michigan adult-use market hitting record sales in March, we’re thrilled to now offer our curated selection of premium cannabis products at High Profile to recreational consumers in Grand Rapids, Kentwood and Wyoming. Whether long-time cannabis connoisseurs or new to the plant, our experienced budtenders can help consumers find the best products to fit their needs and desires. As Michigan is our home, we look forward to bringing six more High Profile locations to the state throughout 2021, expanding convenient access to quality flower and products as demand continues to surge.”
Executive Moves
Find out all about the latest executive moves at:
Top Stories Of The Week
Check out the top stories on Benzinga Cannabis this week:
A study explored the pain-reducing effects
of CBD as well as the impact of the placebo effect on pain
outcomes. The study found CBD and expectancies for receiving CBD
don’t appear to reduce experimental pain intensity but do make
the pain feel less unpleasant. The data showed improvements in pain
measures caused by the pharmacological effects of CBD and the
psychological effects of just expecting they had gotten CBD, which
the researchers called „remarkable and
surprising”. Health Europa
A study found CBD may have vasodilatory
effects in human and rat arteries, however more studies are needed
to determine the effects of CBD on cardiovascular
conditions. The authors suggest CBD may improve a person’s
blood flow, as it widens their blood vessels. Additionally,
a different study explored the effects of a single
dose of CBD oil in healthy participants. The authors found it
lowered blood pressure in individuals who were at rest and those
under stress. Medical News Today
A report examined 3,000 CBD products from
136 companies and found 42% were tested for potency and 13% were
able to provide documentation they tested nearly all their products
for detectable levels of contaminants like heavy metals, pesticides
or microbial content. In some cases, researchers say the results do
exist but weren’t accessible enough through their websites,
which extends to the consumer as well. The report found smaller
brands fared better – those offering seven products or less
were significantly more likely to test most of their products for
both potency and purity when compared with companies offering 40 or
more products. Nutra Ingredients
Delta-8 THC offers the hemp industry commercial promise, but as
delta-8 products increasingly land on store shelves and online
shopping carts, they’re also inviting legislative scrutiny. So
far, delta-8 THC provoked bans in 12 states, including Alaska,
Ariz., Ark., Colo., Del., Ky., Idaho, Iowa, Miss., Mont., R.I. and
Utah. Meanwhile, legislative bans are brewing in other states,
including N.D., Ala. and Ore. The U.S. Hemp Authority, which
certifies hemp products, recently decided not to certify delta-8.
Meanwhile, Fla. lawmakers are moving in the opposite direction, and
established a legal framework for delta-8. Erica Stark, ED of the
National Hemp Association, describes delta-8 as complicated.
Delta-8 is one of more than 100 cannabinoids found in the hemp
plant. The most famous cannabinoid, delta-9 THC, is the compound in
cannabis that tends to get people high. Hemp Grower
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Cannabis & Hemp from United States
Much attention has been paid in recent weeks to President Biden’s infrastructure plan as well as its key sources of funding, including, among other things, raising the corporate tax rate.
Welcome to our weekly roundup of CBD and hemp-related legal and regulatory news:
A study explored the pain-reducing effects of CBD as well as the impact of the placebo effect on pain outcomes. The study found CBD and expectancies for receiving CBD don’t appear to reduce experimental pain intensity but do make the pain feel less unpleasant. The data showed improvements in pain measures caused by the pharmacological effects of CBD and the psychological effects of just expecting they had gotten CBD, which the researchers called “remarkable and surprising”. Health Europa
A study found CBD may have vasodilatory effects in human and rat arteries, however more studies are needed to determine the effects of CBD on cardiovascular conditions. The authors suggest CBD may improve a person’s blood flow, as it widens their blood vessels. Additionally, a different study explored the effects of a single dose of CBD oil in healthy participants. The authors found it lowered blood pressure in individuals who were at rest and those under stress. Medical News Today
A report examined 3,000 CBD products from 136 companies and found 42% were tested for potency and 13% were able to provide documentation they tested nearly all their products for detectable levels of contaminants like heavy metals, pesticides or microbial content. In some cases, researchers say the results do exist but weren’t accessible enough through their websites, which extends to the consumer as well. The report found smaller brands fared better – those offering seven products or less were significantly more likely to test most of their products for both potency and purity when compared with companies offering 40 or more products. Nutra Ingredients
Delta-8 THC offers the hemp industry commercial promise, but as delta-8 products increasingly land on store shelves and online shopping carts, they’re also inviting legislative scrutiny. So far, delta-8 THC provoked bans in 12 states, including Alaska, Ariz., Ark., Colo., Del., Ky., Idaho, Iowa, Miss., Mont., R.I. and Utah. Meanwhile, legislative bans are brewing in other states, including N.D., Ala. and Ore. The U.S. Hemp Authority, which certifies hemp products, recently decided not to certify delta-8. Meanwhile, Fla. lawmakers are moving in the opposite direction, and established a legal framework for delta-8. Erica Stark, ED of the National Hemp Association, describes delta-8 as complicated. Delta-8 is one of more than 100 cannabinoids found in the hemp plant. The most famous cannabinoid, delta-9 THC, is the compound in cannabis that tends to get people high. Hemp Grower
Cannabidiol has been gaining popularity worldwide, thanks to its medicinal and therapeutic properties. Products laced with these hemp extracts effectively treat everything from anxiety to chronic inflammation. The best CBD capsules can also ease several dental issues and PTSD related to dental surgeries or procedures. As a result, dentists who have a more holistic approach to oral health have started prescribing cannabidiol products to patients. But, can cannabidiol help ease dental issues, and if so, how? Here’s a look at everything you need to know about the best CBD capsules and how they help promote oral health.
Can Hemp Products Help Improve Dental Health?
Products containing hemp extracts are some of the hottest new trends in the healthcare and wellness sector. Companies are adding such substances to everything from shampoos and lotions to bath bombs and toothpaste. Recently, dentists have been experimenting with such products hailing them as a natural remedy for anxiety, nerve pain, and more. Additionally, cannabidiol does not produce any mind-altering effects, unlike tetrahydrocannabinol. As a result, products containing these hemp extracts are safer for extended use.
The dental industry can benefit from the anti-inflammatory, anti-oxidative, and analgesic properties of cannabis. Most dental issues arise from inflammation of the gums, which starts as our body’s immune response to an external threat. Over time, such inflammation can give way to sensitivity, discomfort, difficulty chewing, and chronic pain. Hemp extracts can help reduce inflammation and pain sensitivity enabling patients to deal with such symptoms naturally and organically.
How Can Cannabidiol Protect Help Patients?
The best CBD capsules and tinctures may help to protect patients against the following dental issues:
Gum Disease:
While having poor oral hygiene can lead to gum disease, several people are more prone to it through genetics. The most significant contributor to this ailment is the plaque that builds up on our teeth and gums. Such plaque deposition leads to irritation and inflammation, which can cause gingivitis. Over time, it may develop into periodontitis resulting in tooth damage and eventually tooth loss. The anti-inflammatory properties of hemp extracts can help minimize the damage caused by such ailments.
Additionally, such products can help reduce the pain, sensitivity, and discomfort caused due to gum disease. Hemp extracts interact with our body’s CB2 receptors, which help regulate our immune response and functions. As a result, over time, cannabidiol consumption can improve our immune response to gum diseases, leading to healthier gums and teeth.
Tooth Decay:
The primary cause of tooth decay is bacteria found within the mouth that release plaque acids whenever we consume starches or sugars. These Streptococcus mutans bacteria erode enamel and cause cavities that increase in size, allowing more bacterial penetration into our teeth. Once the bacteria reach our pulp, it causes infections leading to sensitivity, pain, and eventually root canal surgeries. By including oils containing hemp extracts in your oral care routine, individuals may help to protect themselves against such bacteria. Cannabidiol possesses potent anti-inflammatory properties that help prevent the decay associated with cavities.
TMJ:
A disorder of the joint connecting our lower jaw to the skull, TMJ can cause debilitating pain and discomfort through erosion, displacement, and inflammation. Over time, the disorder causes chronic jaw pain, difficulty chewing, and jaw locking. While CBD oil does not fix the cause of TMD, certain studies proved that individuals who use cannabidiol achieved relief from their symptoms as it helps reduce pain and swelling. Additionally, these products also decrease sensitivity and soothe pain while also relieving stress and anxiety.
Dental Anxiety:
Roughly 30% of individuals suffer from some degree of dental anxiety, especially if they’ve had even one bad experience as a child. However, habits associated with such disorders, such as grinding of teeth, can cause damage and make it difficult for dentists to perform procedures with ease. Products containing cannabidiol interacts with the receptors and neurotransmitters that process fear, helping ease our nerves. As a result, patients feel much calmer and relaxed before an extraction or root canal, making it easier for dentists to perform a successful procedure. Additionally, such products are also effective in treating post-traumatic stress disorder, helping patients with past trauma handle future appointments.
Toothaches:
Most toothaches result from pulp inflammation that occurs due to bacterial buildup. However, they can be very painful and annoying in the long run. Since cannabidiol acts as an effective treatment for osteoarthritis and possesses potent anti-inflammatory properties, it can work wonders on aches. Additionally, such products also help relax our muscles, making it easier for us to calm our nerves while reducing sensitivity. Bacterial inflammation causes the tooth pulp to swell, and as there is no extra space to allow such expansion, we feel an ache. A similar process happens in joints wherein inflammation causes pain due to enlargement. Hence, the anti-inflammatory properties of hemp can help with such discomfort and pain.
Tooth Sensitivity:
Unlike toothaches that originate from within the teeth, sensitivity arises from the tooth’s external areas. Teeth roots often become porous over time, exposing the nerves inside to sensitivity. As a result, when we bite onto something cold, we feel a dull ache or sharp pain from within the tooth. Such aches and pains come from nerve endings and are not a result of infection. While cannabidiol cannot offer direct help in such cases, it produces a mild analgesic effect that helps soothe such aches. Additionally, patients can fortify and calcify their teeth using fluoride or hydroxyapatite to provide further protection.
Conclusion
As you can see, cannabidiol can provide various benefits to individuals struggling with dental issues. However, consumers should ensure they consult a dentist before administering any treatment to prevent adverse reactions. Additionally, they must conduct enough research to purchase products that address their specific needs and requirements.
Are you curious to learn more about the best CBD products and their role in the dental world? If so why not start doing your research now to gain insight from worldwide credible sources.
As more “Cannabidiol” or CBD products come onto the market, a growing number of truckers are looking into whether using CBD could put their commercial driver’s license (CDL) at risk.
Over the past few years, there has been an explosion of CBD products that promise to reduce anxiety, improve sleep, and reduce every day aches and pains.
In 2020, the U.S. Department of Transportation issued guidance about CBD use for safety-sensitive employees in the transportation industry, including pilots, train engineers, and truck drivers.
In the notice, DOT reminds workers that it is never acceptable for safety-sensitive employees who are subject to drug testing regulations to consume marijuana.
Workers are also warned to use caution if they do decide to consume CBD:
“Since the use of CBD products could lead to a positive drug test result, Department of Transportation-regulated safety-sensitive employees should exercise caution when considering whether to use CBD products.”
The notice outlines three major points about the use of CBD by safety-sensitive workers:
The Department of Transportation requires testing for marijuana and not CBD.
The labeling of many CBD products may be misleading because the products could contain higher levels of THC than what the product label states. The Food and Drug Administration (FDA) does not currently certify the levels of THC in CBD products, so there is no Federal oversight to ensure that the labels are accurate. The FDA has cautioned the public that: “Consumers should beware purchasing and using any [CBD] products.” The FDA has stated: “It is currently illegal to market CBD by adding it to a food or labeling it as a dietary supplement.”* Also, the FDA has issued several warning letters to companies because their products contained more CBD than indicated on the product label.
The Department of Transportation’s Drug and Alcohol Testing Regulation, Part 40, does not authorize the use of Schedule I drugs, including marijuana, for any reason. Furthermore, CBD use is not a legitimate medical explanation for a laboratory-confirmed marijuana positive result. Therefore, Medical Review Officers will verify a drug test confirmed at the appropriate cutoffs as positive, even if an employee claims they only used a CBD product.
